Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP7 | P09237 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 2/20 | 0.35 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.34 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.34 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25880720 | 0.88 | MMP13 (0.38) | ALDH1A1MMP1MMP2MMP3MMP7 | |
| SCHEMBL25877986 | 0.88 | SLC1A3 (0.38) | HSD11B1 | |
| SCHEMBL25664460 | 0.87 | ALDH1A1 (0.36) | HSD11B1ALDH1A1MMP1MMP2MMP3 | |
| SCHEMBL25880760 | 0.83 | MMP13 (0.37) | MMP1MMP2MMP3MMP7MMP9 | |
| SCHEMBL25880702 | 0.83 | ADAM17 (0.40) | — | |
| SCHEMBL25877328 | 0.83 | MMP7 (0.42) | MMP1MMP2MMP3MMP7MMP9 | |
| SCHEMBL25878425 | 0.82 | CTSV (0.31) | — | |
| SCHEMBL25878005 | 0.81 | MMP13 (0.40) | ALDH1A1MMP1MMP2MMP3MMP7 | |
| SCHEMBL25878129 | 0.80 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL26269872 | 0.80 | SLC1A3 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234921-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234921-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | SERPINB1, CTSV, CTSE | HSD11B1 3617/4885ALDH1A1 2826/4885MMP1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.